An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma

• मुख्य लेखकों: Astrid De Meulenaere (लेखक), Tijl Vermassen (लेखक), David Creytens (लेखक), Stijn De Keukeleire (लेखक), Tim Delahaye (लेखक), Philippe Deron (लेखक), Fréderic Duprez (लेखक), Samson Fung (लेखक), Patrick Pauwels (लेखक), Liesbeth Ferdinande (लेखक), Sylvie Rottey (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2021-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract CD70 is expressed in up to 80% of nasopharyngeal carcinoma (NPC) cases. Cusatuzumab is a humanized anti‐CD70 monoclonal antibody, with dual action mechanisms: induction of cytotoxicity against CD70+ tumor cells and reduction in CD70‐CD27 signaling mediated immune evasion. The aim of this st...